Follow-up in neuroblastoma: Comparison of metaiodobenzylguanidine and a chimeric anti-gd2 antibody for detection of tumor relapse and therapy response

American Journal of Pediatric Hematology/Oncology

Volumn 23, Issue 7, 2001, Pages 437-442

  Reuland, Peter ^a   Geiger, Livia ^a   Thelen, Marcel H ^a   Handgretinger, Rupert ^a   Haase, Bernd ^c   Müller Schauenburg, Wolfgang ^a   Niethammer, Dietrich ^a   Bares, Roland ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Behring Company   (Germany)

Author keywords

Chimeric GD2 antibody; Mibg; Neuroblastoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; CHIMERIC ANTIBODY; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2; MONOCLONAL ANTIBODY CH14.18 TC 99M; MONOCLONAL ANTIBODY TC 99M; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BONE METASTASIS; CANCER RECURRENCE; CANCER STAGING; CHILD; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; IMMUNOSCINTIGRAPHY; LYMPH NODE METASTASIS; MALE; NEUROBLASTOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SOFT TISSUE CANCER;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; FALSE NEGATIVE REACTIONS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW-UP STUDIES; GANGLIOSIDES; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROBLASTOMA; RADIOPHARMACEUTICALS; RECOMBINANT FUSION PROTEINS; SOFT TISSUE NEOPLASMS; TECHNETIUM;

EID: 0034755666     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200110000-00009     Document Type: Article

References (19)

1. Brodeur GM, Seeger RC, Barret A, et al. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. Prog Clin Biol Res 1988; 271: 509-24.
2. Gillies SD, Lo KM, Wesolowski J. High level expression of chimeric antibodies using adopted cDNA variable region cassettes. J Immunol Methods 1989; 125: 191-202.
3. Handgretinger R, Kimmig A, Lang P, et al. Interferon-gamma up-regulates the susceptibility of human neuroblastoma cells tointerleukin-2-activated natural killer cells. Nat Immun Cell Growth Regul 1989; 8: 189-96.
4. Handgretinger R, Baader P, Dopfer R, et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 1992; 35: 199-204.
5. Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995; 31A (2): 261-7.
6. Hoefnagel CA. The clinical use of 131I-metaiodobenzylguanidine (MIBG) for the diagnosis and treatment of neural crest tumors. Amsterdam: Academisch Proefschrift der Universität Amsterdam, 1989.
7. Klingebiel T, Feine U, Treuner J, et al. Treatment of neuroblastoma with (131I) metaiodobenzylguanidine: Long-term results in 25 patients. J Nucl Biol Med 1991; 35: 216-9.
8. Maurea S, Lasteria S, Caraco C, et al. Iodine-131-MIBG Imaging to Monitor Chemotherapy Response in Advanced Neuroblastoma: Comparison with Laboratory Analysis. J Nucl Med 1994; 35: 1429-35.
9. Miceli A, Nespoli L, Burgio GR, et al. The role of meta-iodo (131I)benzylguanidine (MIBG) in the diagnosis and follow-up of neuroblastoma. Pediatr Hematol Oncol 1986; 3: 37-47.
10. Mujoo K, Kipps THJ, Yang HM, et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res 1989; 49: 2857-61.
11. Reisfeld RA, Cheresh DA. Human tumor antigens. In: Dixon FJ, ed. Advanced Immunology. New York: Academic Press, 1987, 323-77.
12. Reuland P. Nuklearmedizinische Untersuchungen bei embryonalen Tumoren. Tübingen, Germany: Universität Tübingen, 1991.
13. Reuland P, Klingebiel TH, Dopfer R, et al. Anwendung von Interleukin 2 bei einem Kind mit Stadium IV Neuroblastom nach Chemotherapie, Therapie mit 131Jod meta-Jodobenzylguanidin (m-IBG) und Knochenmarktransplantation. Nuc Compact 1989; 20: 138-41.
14. Reuland P, Handgretinger R, Smykowsky H, et al. Application of the Murine Anti-Gd-2 Antibody 14.Gd-2a for Diagnosis and Therapy of Neuroblastoma. Nucl Med Biol 1991; 18: 121-5.
15. Schwarz A, Steinsträér A. A novel approach to Tc-99m-labeled monoclonal antibodies (abstract). J Nucl Med 1987; 28: 721.
16. Shapiro B, Copp JE, Sisson JC, et al. iodine-131-metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experiences in 400 cases. J Nucl Med 1985; 26:576-85.
17. Treuner J, Feine U, Niethammer D, et al. Scintigraphic imaging of neuroblastoma with 131I-Iodobenzylguanidine. Lancet 1984; 11: 333-4.
18. Yeh SDJ, Kushner B, Sullivan M, et al. Potentials for neuroblastoma imaging and target radiotherapy. A comparison between I-131 3F8 and I-131 mIBG. J Nucl Med 1988; 29: 84.
19. Yeh SDJ, Larson SM, Burch L, et al. Radioimmunodetection of neuroblastoma with iodine-131-3F8: Correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities. J Nucl Med 1991; 32: 769-776.